Literature DB >> 17719070

Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.

Gregory D Gromowski1, Alan D T Barrett.   

Abstract

The surface of the mature dengue virus (DENV) particle consists of 90 envelope (E) protein dimers that mediate both receptor binding and fusion. The E protein ectodomain can be divided into three structural domains designated ED1, ED2, and ED3, of which ED3 contains the critical and dominant virus-specific neutralization sites. In this study the ED3 epitopes recognized by seven, murine, IgG1 DENV-2 type-specific, monoclonal antibodies (MAbs) were determined using site-directed mutagenesis of a recombinant DENV-2 ED3 (rED3) protein. A total of 41 single amino acid substitutions were introduced into the rED3 at 30 different surface accessible residues. The affinity of each MAb with the mutant rED3s was assessed by indirect ELISA and the results indicate that all seven MAbs recognize overlapping epitopes with residues K305 and P384 critical for binding. These residues are conserved among DENV-2 strains and cluster together on the upper lateral face of ED3. A linear relationship was observed between relative occupancy of ED3 on the virion by MAb and neutralization of the majority of virus infectivity ( approximately 90%) for all seven MAbs. Depending on the MAb, it is predicted that between 10% and 50% relative occupancy of ED3 on the virion is necessary for virus neutralization and for all seven MAbs occupancy levels approaching saturation were required for 100% neutralization of virus infectivity. Overall, the conserved antigenic site recognized by all seven MAbs is likely to be a dominant DENV-2 type-specific, neutralization determinant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719070     DOI: 10.1016/j.virol.2007.05.042

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  100 in total

1.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

2.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

3.  Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity.

Authors:  Poornima Parameswaran; Patrick Charlebois; Yolanda Tellez; Andrea Nunez; Elizabeth M Ryan; Christine M Malboeuf; Joshua Z Levin; Niall J Lennon; Angel Balmaseda; Eva Harris; Matthew R Henn
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

4.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

6.  New vaccine development for chronic brain disease.

Authors:  Alan Dt Barrett; Rakez Kayed; George R Jackson; Kathryn A Cunningham
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E.

Authors:  Stefan Kiermayr; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

8.  Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes.

Authors:  Lidice Bernardo; Osmel Fleitas; Alequis Pavón; Lisset Hermida; Gerardo Guillén; Maria G Guzman
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

9.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1.

Authors:  Yang Zhou; S Kyle Austin; Daved H Fremont; Boyd L Yount; Jeremy P Huynh; Aravinda M de Silva; Ralph S Baric; William B Messer
Journal:  Virology       Date:  2013-02-28       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.